Business Description
Janux Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US47103J1051
Share Class Description:
JANX: Ordinary SharesDescription
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing next-generation therapeutics based on proprietary tumor activated T Cell Engager platform technology to treat patients suffering from cancer.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 28.08 | |||||
| Equity-to-Asset | 0.94 | |||||
| Debt-to-Equity | 0.04 | |||||
| Debt-to-EBITDA | -0.28 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 37 | |||||
| Beneish M-Score | -2.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -45.3 | |||||
| 3-Year EPS without NRI Growth Rate | -34.4 | |||||
| 3-Year FCF Growth Rate | -50.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate | -17.62 |
Momentum Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 25.47 | |||||
| 9-Day RSI | 30.58 | |||||
| 14-Day RSI | 35.69 | |||||
| 6-1 Month Momentum % | 13.89 | |||||
| 12-1 Month Momentum % | 471.84 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 38.8 | |||||
| Quick Ratio | 38.8 | |||||
| Cash Ratio | 38.32 | |||||
| Days Sales Outstanding | 112.15 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -5 | |||||
| Shareholder Yield % | -13.44 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -658.76 | |||||
| Net Margin % | -463.91 | |||||
| FCF Margin % | -289.85 | |||||
| ROE % | -11.37 | |||||
| ROA % | -10.65 | |||||
| ROIC % | -235.43 | |||||
| ROC (Joel Greenblatt) % | -316.98 | |||||
| ROCE % | -15.48 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 180.84 | |||||
| PB Ratio | 3.61 | |||||
| Price-to-Tangible-Book | 3.61 | |||||
| EV-to-EBIT | -20.22 | |||||
| EV-to-Forward-EBIT | -17.75 | |||||
| EV-to-EBITDA | -20.72 | |||||
| EV-to-Forward-EBITDA | -18.05 | |||||
| EV-to-Revenue | 133.2 | |||||
| EV-to-Forward-Revenue | 97.68 | |||||
| EV-to-FCF | -45.96 | |||||
| Price-to-Net-Current-Asset-Value | 3.77 | |||||
| Price-to-Net-Cash | 3.82 | |||||
| Earnings Yield (Greenblatt) % | -4.95 | |||||
| FCF Yield % | -1.59 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:JANX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Janux Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 13.049 | ||
| EPS (TTM) ($) | -1.16 | ||
| Beta | 3.52 | ||
| Volatility % | 470.09 | ||
| 14-Day RSI | 35.69 | ||
| 14-Day ATR ($) | 2.867112 | ||
| 20-Day SMA ($) | 50.9125 | ||
| 12-1 Month Momentum % | 471.84 | ||
| 52-Week Range ($) | 7.79 - 65.6 | ||
| Shares Outstanding (Mil) | 52.48 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Janux Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Janux Therapeutics Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Janux Therapeutics Inc Frequently Asked Questions
What is Janux Therapeutics Inc(JANX)'s stock price today?
The current price of JANX is $45.21. The 52 week high of JANX is $65.60 and 52 week low is $7.79.
When is next earnings date of Janux Therapeutics Inc(JANX)?
The next earnings date of Janux Therapeutics Inc(JANX) is 2025-02-06 Est..
Does Janux Therapeutics Inc(JANX) pay dividends? If so, how much?
Janux Therapeutics Inc(JANX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers